Sema4 reports it has entered into a strategic agreement with Merus, a Dutch company, to utilize Sema4’s advanced genomic testing to identify patients with tumors harboring neuregulin 1 gene (NRG1) fusions who may be eligible for investigational treatment with the bispecific antibody Zenocutuzumab (“Zeno”) in a Phase 1/2 eNRGy trial sponsored by Merus.
NRG1 gene fusions are a group of rare genomic alterations emerging as a potential actionable driver of tumorigenesis and growth across many types of solid tumors, including lung, breast, pancreatic, ovarian, and colorectal cancers. Zeno, through its unique mechanism of blocking the interaction of the NRG1 fusion protein with its receptor HER3, has the potential to be particularly effective against NRG1+ cancers.